3.19 USD
-0.02
0.62%
At close Apr 22, 4:00 PM EDT
Pre-market
3.23
+0.04
1.25%
1 day
-0.62%
5 days
-2.45%
1 month
6.33%
3 months
-19.44%
6 months
16.00%
Year to date
-7.54%
1 year
26.09%
5 years
-94.29%
10 years
-94.29%
 

About: CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.

Employees: 1,088

0
Funds holding %
of 7,419 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

12% more call options, than puts

Call options by funds: $322K | Put options by funds: $288K

1.46% less ownership

Funds ownership: 4.97% [Q3] → 3.5% (-1.46%) [Q4]

6% less funds holding

Funds holding: 80 [Q3] → 75 (-5) [Q4]

13% less repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 24

19% less capital invested

Capital invested by funds: $32.8M [Q3] → $26.6M (-$6.19M) [Q4]

24% less first-time investments, than exits

New positions opened: 13 | Existing positions closed: 17

100% less funds holding in top 10

Funds holding in top 10: 1 [Q3] → 0 (-1) [Q4]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target
$16
402%
upside
Avg. target
$16
402%
upside
High target
$16
402%
upside

1 analyst rating

positive
100%
neutral
0%
negative
0%
JMP Securities
Roy Buchanan
13% 1-year accuracy
3 / 24 met price target
402%upside
$16
Market Outperform
Reiterated
14 Feb 2025

Financial journalist opinion

Based on 8 articles about CVAC published over the past 30 days

Neutral
Seeking Alpha
1 week ago
CureVac N.V. (CVAC) Q4 2024 Earnings Call Transcript
CureVac N.V. (NASDAQ:CVAC ) Q4 2024 Earnings Conference Call April 10, 2025 9:00 AM ET Company Participants Sarah Fakih - Vice President, Corporate Communications and Investor Relations Alexander Zehnder - Chief Executive Officer Myriam Mendila - Chief Scientific Officer Axel Sven Malkomes - Chief Financial Officer Conference Call Participants Alec Stranahan - Bank of America Ryan McElroy - Leerink Partners Roger Song - Jefferies Jasmine Fels - UBS Roy Buchanan - Citizens JMP Jonathan Miller - Evercore ISI Chiara Montironi - Kempen Operator Greetings.
CureVac N.V. (CVAC) Q4 2024 Earnings Call Transcript
Neutral
Accesswire
1 week ago
CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2024 and Provides Business Update
Strategic Milestone Achievement and Increased Financial Discipline Underscore Year of Corporate Transformation Completed enrollment of Part B of Phase 1 glioblastoma study with investigational precision immunotherapy CVGBM; Part B first data readout anticipated in H2 2025 Filed IND and CTA submissions for Phase 1 study with proprietary off-the-shelf program in squamous non-small cell lung cancer (sqNSCLC) Received FDA clearance to proceed with sqNSCLC Phase 1 study; expected to  start in H2 2025 Invoiced €10 million milestone payment following initiation of Phase 1 of the combined Phase 1/2 study of a seasonal influenza/COVID-19 combination vaccine; program fully licensed to GSK Received positive validity decision for patent EP 3 708 668 B1 in amended form from European Patent Office (EPO) in inter partes proceedings against BioNTech SE Jury trial in U.S. litigation postponed to September 8, 2025, by the District Court of the Eastern District of Virginia Cash and cash equivalents position of €481.7 million as of December 31, 2024; reaffirming expected cash runway into 2028 CureVac to host conference call and webcast today at 9 a.m. EST / 3 p.m.
CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2024 and Provides Business Update
Neutral
Accesswire
2 weeks ago
CureVac to Report Fourth Quarter and Full-Year 2024 Financial Results and Business Update on April 10, 2025
TÜBINGEN, DE / ACCESS Newswire / April 8, 2025 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biotech company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), will report financial results, and provide business updates for the fourth quarter and full-year 2024 on Thursday, April 10, 2025.
CureVac to Report Fourth Quarter and Full-Year 2024 Financial Results and Business Update on April 10, 2025
Neutral
Accesswire
2 weeks ago
CureVac Receives U.S. FDA IND Clearance to Initiate Phase 1 Clinical Trial for Novel mRNA-Based Precision Immunotherapy in Squamous Non-Small Cell Lung Cancer
Significant Regulatory Milestone: U.S. FDA cleared IND application for CVHNLC, CureVac's investigational therapy targeting squamous non-small cell lung cancer Proprietary Epitopes: CVHNLC encodes novel tumor epitopes identified through proprietary whole genome-based discovery platform Enhanced Combination Therapy: CVHNLC to be tested in combination with pembrolizumab, aiming to amplify targeted anti-tumor immune responses Clinical Progress: Patient treatment anticipated to start in the second half of 2025 Pipeline Advancement: IND clearance highlights CureVac's continued oncology pipeline growth, with more candidates planned to enter the clinic in 2026 TÜBINGEN, GERMANY AND BOSTON, MA / ACCESS Newswire / April 7, 2025 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biotech company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for a Phase 1 clinical study of CVHNLC in patients with squamous non-small cell lung cancer (sqNSCLC).
CureVac Receives U.S. FDA IND Clearance to Initiate Phase 1 Clinical Trial for Novel mRNA-Based Precision Immunotherapy in Squamous Non-Small Cell Lung Cancer
Positive
Market Watch
3 weeks ago
CureVac Shares Rise on Patent Confirmation Amid BioNTech Lawsuit
Shares of CureVac climbed after the European Patent Office confirmed the validity of a patent that has been the subject of a lawsuit filed by BioNTech.
CureVac Shares Rise on Patent Confirmation Amid BioNTech Lawsuit
Positive
Benzinga
3 weeks ago
European Patent Office Rules Vaccine Developer CureVac's Amended Patent Valid, Stock Jumps
CureVac N.V. CVAC on Thursday said the European Patent Office (EPO) confirmed the validity of CureVac's European patent EP 3 708 668 B1 subject to amendments to specify the scope of protection.
European Patent Office Rules Vaccine Developer CureVac's Amended Patent Valid, Stock Jumps
Positive
Reuters
3 weeks ago
European Patent Office declares CureVac mRNA patent valid
The European Patent Office declared a patent owned by CureVac , valid, after a challenge from drugmaker BioNTech , the company said on Thursday.
European Patent Office declares CureVac mRNA patent valid
Neutral
Accesswire
3 weeks ago
CureVac Receives Positive Validity Decision from European Patent Office in Litigation Against BioNTech SE
European Patent Office largely dismisses opposition filed by BioNTech SE in April 2023 challenging validity of EP 3 708 668 B1 and maintains the patent in amended form A hearing on infringement of EP 3 708 668 B1 is scheduled for July 1, 2025, before the Regional Court Düsseldorf Confirming validity of patent in its amended form marks major milestone in broader patent litigation in Germany, recognizing CureVac's pioneering mRNA innovation TÜBINGEN, GERMANY AND BOSTON, MA / ACCESS Newswire / March 27, 2025 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced that the European Patent Office (EPO) has confirmed the validity of CureVac's European patent EP 3 708 668 B1 subject to amendments to specify the scope of protection.
CureVac Receives Positive Validity Decision from European Patent Office in Litigation Against BioNTech SE
Neutral
Accesswire
2 months ago
CureVac Earns Repeat Recognition by LexisNexis(R) as One of the World's Top Innovators
CureVac among global top 100 most fast-paced innovators for third consecutive year in acknowledgment of its innovative strength and extensive intellectual property portfolio The company holds one of the broadest intellectual property portfolios in mRNA technology TÜBINGEN, GERMANY AND BOSTON, MA / ACCESS Newswire / February 18, 2025 / CureVac N.V. (Nasdaq:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced its recognition as a Top 100 Global Innovator in the Innovation Momentum 2025 report by LexisNexis®.
CureVac Earns Repeat Recognition by LexisNexis(R) as One of the World's Top Innovators
Positive
Seeking Alpha
3 months ago
CureVac: Latest GBM Data Bodes Well For Next Program Check Point
CureVac N.V.'s CVGBM vaccine showed positive safety and immunogenicity data in Part A of its phase 1 study for resected glioblastoma, with no dose-limiting toxicities. Key catalysts include Part B CVGBM resectable GBM data release in 2nd half of 2025 and possible phase 2 study initiation in 2nd half of 2026. The company is also developing a vaccine for squamous NSCLC, with an IND filing expected in the 1st half of 2025 and phase 1 study initiation in the 2nd half of 2025.
CureVac: Latest GBM Data Bodes Well For Next Program Check Point
Charts implemented using Lightweight Charts™